The formation of the strong oxidant methylglyoxal, an a-oxo-aldehyde, is increased in hyperglycaemia which is associated with both Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus in humans [1] . The glyoxalase system, consisting of two enzymes (glyoxalase I and glyoxalase II) and one cofactor, glutathione (GSH) [2] , plays an important role in scavenging methylglyoxal. Glyoxalase I catalyses the formation of S-D-lactoylglutathione from the hemithioacetal that is formed nonenzymatically from methylglyoxal and GSH. Glyoxalase II hydrolyses S-D-lactoylglutathione to D-lac- Diabetologia (2001) Abstract Aims/hypothesis. The hyperglycaemia associated with diabetes causes excessive production of cytotoxic methylglyoxal, an a-oxo-aldehyde. The glyoxalase system, composed of glyoxalase I and glyoxalase II, with glutathione (GSH) as the cofactor, plays an important role in the detoxification of a-oxo-aldehydes. We tested the hypothesis that troglitazone, an insulin-sensitizing drug previously used in the treatment of Type II (non-insulin-dependent) diabetes mellitus, up-regulates the glyoxalase system either by increasing phase 2 enzyme activities and thereby increasing cellular GSH, or, by inducing glyoxalase enzyme activities. Methods. Human astroglial cells, rat hepatocytes and cardiac myocytes were cultured and exposed to either troglitazone, or tertiary-butylhydroquinone (tBHQ, a phase 2 enzyme inducer). Glutathione content, advanced glycation end products (AGEs) and enzyme (glyoxalase I, glyoxalase II as well as the phase 2 enzymes, glutathione S-transferase and thioredoxin reductase) activities were determined. Glyoxalase I mRNA was also measured.
Results. Troglitazone had no effect on cellular GSH nor phase 2 enzyme activities but significantly reduced the activities of glyoxalase I and II; this inhibitory effect was concentration-dependent and timedependent and was associated with reduced mRNA contents and increased AGEs formation. Rosiglitazone had no effect on glyoxalase I gene expression. tBHQ, a classic phase 2 enzyme inducer, had no effect on the glyoxalase system but did increase glutathione contents and the activities of glutathione S-transferase and thioredoxin reductase. Conclusion/interpretation. Our study shows that troglitazone is a selective inhibitor of the glyoxalase system. This inhibition of the glyoxalase system could contribute to troglitazone's hepatotoxic action which has previously been reported in a small percentage of individuals. [Diabetologia (2001) 44: 2004±2012] Keywords Advanced glycation end products, diabetes mellitus, gene expression regulation, hepatotoxicity, hypoglycaemic agents, insulin resistance, oxidative stress.
tate, regenerating GSH. The accumulation of a-oxoaldehydes including methylglyoxal due to an impaired detoxification function of glyoxalase system could result in protein glycation, DNA damage [1] , vascular dysfunction and atherosclerosis [3] . These observations indicate that the glyoxalase system plays an important role in the causation and maintenance of diabetic vascular complications. Indeed, reduced activity in the glyoxalase system has been reported in streptozotocin-diabetic MF1 mice [4] and rats [5] . An up-regulation of glyoxalase activities in diabetes would be expected to reduce methylglyoxal concentrations and to slow down or reverse the protein glycation process. Indeed, cell glyoxalase I transfectant lines have an increased ability to scavenge methylglyoxal and tolerate higher levels of methylglyoxal (6) . Furthermore, metformin, an antihyperglycaemic drug, reduces methylglyoxal concentrations in Type II diabetic patients [7] .
Troglitazone, a member of the thiazolidinedione family, is an antidiabetic agent that has been used clinically in the management of Type II diabetes because it can improve sensitivity of muscle and adipose tissues to insulin and can inhibit hepatic gluconeogenesis [8±10] . Troglitazone also has an antihypertensive effect [11] and inhibits vascular smooth muscle cell growth [12] . Some of the antihyperglycaemic actions appear to be through down-regulation of the expression of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase [13] and up-regulation of c-Cbl-associated protein [14] . At the molecular level, a major mode of action of troglitazone is binding and activating the Peroxisome Proliferator Activated Receptor-g (PPAR-g) that regulates the transcription of a number of genes, including insulin responsive genes, critical for the control of glucose and lipid metabolism [15] .
Troglitazone has been reported to have antioxidant activity. It has a moiety structurally similar to vitamin E and has been reported to protect low-density lipoprotein (LDL) from oxidative modification [16] . We questioned whether troglitazone could decrease oxidative stress by other mechanisms. Overexpression of glyoxalase I in bovine endothelial cells has been shown to prevent the hyperglycaemia-induced protein glycation [17] . There has been no study on the possible effect of troglitazone on the glyoxalase system. We hypothesized that possibly troglitazone: 1) up-regulates the glyoxalase system, or, 2) acts as a phase 2 enzyme inducer [18] and thereby increases GSH by up-regulating g-glutamyl-cysteinyl synthase, the rate-limiting enzyme in GSH synthesis [19] which is under the control of the anti-oxidant response element [20] . An increase in the GSH would not only facilitate the detoxification of a-oxo-aldehydes by glyoxalase system but also reduce the oxidative stress by a variety of other mechanisms [21] . As a positive control for up-regulation of phase 2 enzymes, we also examined the effect of the phase 2 enzyme inducer, tertiary-butylhydroquinone (tBHQ).
Materials and methods
Cell preparation. Three cell preparations were used in this study. One was H11 human astroglioma cells clonally derived from a proliferating glial population in cultures established from adult human temporal lobe resected because of intractable epilepsy [22] . H11 cells were plated in 60-mm dishes in DMEM containing 10 % FCS and incubated at 37 C in a humidified atmosphere comprised of 5 % CO 2 in air. Cells were used for experimentation when cultures attained confluency. The second cell type examined was the H9c2 rat cardiac myocyte [23] obtained from the American Type Tissue Collection. These cells were grown in DMEM containing 10 % FCS.
Rat hepatocytes in primary culture were also used. Hepatocytes were isolated from Sprague-Dawley rats using the collagenase perfusion method [24] and cells placed on collagen coated 100 mm dishes at a concentration of 2 million cells per dish. After a 4-h incubation in the presence of DMEM containing 10 % FBS, the medium was replaced with serum-free DMEM containing 0.2 % bovine serum albumin and incubated for another additional 8 h and then treated for 8 h with troglitazone, rosiglitazone or dimethylsulfoxide (DMSO) vehicle. Animals were treated in accordance with the guidelines of the Canadian Council on Animal Care.
Measurement of enzyme activities. The activities of glyoxalase I and glyoxalase II were determined following McLellan and Thornalley's method [25] . In brief, the activity of glyoxalase I was evaluated by monitoring the increase in absorbance at 240 nm due to the formation of S-D-lactoylgutathione and that of glyoxalase II by monitoring the decrease at 240 nm due to the hydrolysis of S-D-lactoylgutathione in the presence of homogenates. The activity of glutathione S-transferase was measured by monitoring the change in the absorbance at 340 nm due to the thioether formation in the presence of homogenates [26] . The activity of thioredoxin reductase in the homogenates was measured by monitoring the changes in the absorbance at 412 nm due to the reduction of 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) in the presence of NADPH [27] as we have previously done [28] . Protein concentrations were determined by bicinchoninic acid procedure [29] using bovine serum albumin as the reference.
Measurement of GSH contents. The monochlorobimane procedure was used to measure GSH contents as described previously [30] . The GSH-monochlorobimane adduct was measured using a Labsystems Fluoroskan II (MTX Lab Systems, Vienna, Va., USA) microtitre fluorometric reader with excitation at 380 nm and emission measured at 470 nm.
Measurement of oxidative stress. Oxidative stress was determined as described in our previous publication [31] . Briefly, cells were preloaded with a membrane permeable agent 5-(and-6)-carboxy-2'7'-dichlorodihydrofluorescein ester (DCFH ester) for 30 min before different treatments. The DCFH ester becomes the membrane impermeable DCFH in the presence of cytosolic esterases. DCFH is oxidized to the fluorescent DCF principally by strong oxidants. Oxidative stress was determined by monitoring the DCF content with the microtitre fluorometer with excitation at 495 nm and emission at 525 nm.
Measurement of advanced glycation end products. Methylglyoxal as well as other a-oxo-aldehydes interact with proteins to form advanced glycation end products (AGEs) that fluoresce at 440 nm when excited at 370 nm [32, 33] ; hence, AGEs were measured fluorometrically in medium serum and in cell protein of H11 astroglioma cell cultures.
Northern blot. A 622 bp glyoxalase probe [34] was isolated from a 2.69 Kb pUC vector (a generous gift from Dr. K. Tew) using EcoRI. Total RNA was isolated using TriZol Reagent (Gibco/BRL, Burlington, Ontario, Canada). For determining equivalency of RNA loading the ribosomal phosphoprotein PO (RPPO) cDNA was used [35] . cDNA probes were random-labelled with [a-
32 P]dCTP according to the instructions supplied with the hexanucleotide kit (Boehringer Mannheim, Laval, Quebec, Canada).
Northern blot analysis was done by electrophoresing RNA (20 mg) through a 1 % agarose-formaldehyde gel, followed by transfer of RNA to GeneScreen Plus membranes (DuPontNew England Nuclear, Boston, Mass., USA), capillary elution and UV-crosslinking to the membrane at 254 nm (1200 mW/ cm 2 , Stratalinker 1800, Stratagene, La Jolla, Calif., USA). The RNA was hybridized to the cDNA probes (10´10 6 cpm) in 5 x SSPE (0.75 mol/l NaCl, 50 mmol/l NaH 2 PO 4 , 5 mmol/l EDTA, pH 7.4), 0.5 % sodium dodecylsulfate, 5´Denhardt's solution, 10 % dextran sulfate containing 100 mg/ml denatured salmon sperm for 16±20 h in a rotary hybridization oven (TurboSpeed, Bio/Can Scientific, Mississauga, Ontario, Canada) at 65 C. Following hybridization, membranes were washed with 2´SSPE, 0.1 % SDS at room temperature followed by 1 SSPE, 0.1 % SDS at 65 C. The membranes were exposed to x-ray film at ±80 C, developed and autoradiograms were scanned and quantified using NIH Image software.
Chemicals and data analysis. Troglitazone was a gift from Parke-Davis (Ann Arbor, Mich., USA) while rosiglitazone was a gift from Smith-Kline Beecham (West Sussex, UK). GSH, tBHQ, xanthine, xanthine oxidase, S-D-lactoylgutathione, 1-chloro-2,4-nitrobenzene, DMSO and glutathione Stransferase were purchased from Sigma Chemical Co (St. Louis, Mo., USA). Monochlorobimane and DCFH ester were purchased from Molecular Probes (Eugene, Ore., USA). Troglitazone and tBHQ were prepared in DMSO and the final concentration of DMSO in the medium was 0.1 %. There were no differences in the activities of glyoxalases, the contents of GSH or oxidative stress in the absence or presence of DMSO (0.1 %) in the cells. Data are expressed as means SEM and analysed using Student's t test or analysis of variance in conjunction with the Newman-Keuls test where applicable. Differences between groups were considered statistically significant when p < 0.05.
Results
The effect of troglitazone on the activities of glyoxalases. H11 cells were cultured for 24 h with troglitazone or tBHQ. Troglitazone significantly inhibited the activity of glyoxalase I in a concentration-dependent manner with maximal inhibition seen at 50 mmol/l (Fig. 1A) . After H11 cells were treated with 50 mmoles/l troglitazone, for instance, the activity of glyoxalase I was decreased by 56 8 % compared to the control group (p < 0.05, n = 6); however, there was no change in the activity of glyoxalase I after the cells were treated with tBHQ (Fig. 1A) . Fig. 1B shows that the activity of glyoxalase II in H11 cells was significantly reduced by 63 5 % after the treatment with 100 mmoles/l troglitazone, but not with tBHQ (100 mmoles/l).
To determine whether troglitazone inhibited glyoxalase I activity in another cell type, rat hepatocytes grown in primary culture were exposed to troglitazone and glyoxalase I activity measured after 8 h revealing a dose-dependent troglitazone-induced decrease in glyoxalase I activity (Fig. 2) .
The effect of troglitazone on the cellular GSH contents and the activities of phase 2 enzymes. To investigate whether the troglitazone-induced inhibition of glyoxalases was coupled to the regulation of cellular GSH contents, H11 cells were incubated with troglitazone for 24 h and then the cellular GSH contents were measured. Figure 3 shows that troglitazone at different concentrations (25 to 100 mmol/l) did not signifi-A B Fig. 1 . Effect of a 24-h exposure of troglitazone or tBHQ on the activities of glyoxalases in H11 cells. A The concentrationdependent effects of troglitazone (*) and tBHQ (*) on the activity of glyoxalase I. B The effects of troglitazone (100 mmol/l) and tBHQ (100 mmol/l) on the activity of glyoxalase II. n = 6 in A and n = 4 in B per data point . * indicates p < 0.05, compared to control group cantly change the GSH contents. In contrast, 24 h incubation with tBHQ induced a significant increase in GSH contents in these cells.
Whether troglitazone or tBHQ could modify the activity of the phase 2 enzymes in H11 cells was examined. Troglitazone (25 to 100 mmol/l) did not induce a significant change in the activity of glutathione S-transferase, although tBHQ increased the activities of this phase 2 enzyme in these cells (Fig. 4A) . In addition to GSH, thioredoxin as an electron donor can also protect protein sulfhydryls from oxidation [36] . The oxidized-thioredoxin is reduced by thioredoxin reductase [27] . Figure 4B shows no significant changes in the activity of thioredoxin reductase after incubating the cells with troglitazone for 24 h. However, tBHQ, significantly increased the activity of thioredoxin reductase in these cells.
The effect of troglitazone on formation of advanced glycation endproducts. To determine whether a reduction in glyoxalase activities is associated with increased methylglyoxal-associated cell damage, the formation of AGEs in H11 astroglioma cells was examined. There was a significant increase in AGE formation following a 24 h exposure to troglitazone, both in medium and in cells (Fig. 5 ) .
The effects of troglitazone on oxidative stress. A significant increase in the oxidative stress, as measured by oxidation of DCFH and as compared with the control group, was observed after the H11 cells were treated for 24 h with troglitazone at the concentrations of 50 or 100 mmol/l. In contrast, the treatment of the cells with tBHQ for 24 h resulted in a reduction in the oxidative stress (Fig. 6) . A linear regression analysis of GSH contents against the oxidative stress levels showed that changes of oxidative stress bore no relation to cellular GSH content in the presence of troglitazone (r = ±0.05, p > 0.05). However, a negative correlation between the GSH contents and oxi- Fig. 2 . The effect of an 8 h exposure of troglitazone on glyoxalase I activity in primary cultures of rat hepatocytes prepared from three different rats. Note that n = 4 for each data point except for 25 mmol/l troglitazone where n = 3. *indicates p < 0.05, compared to the control group were evaluated. Troglitazone had no effect on the activities of both phase 2 enzymes, but tBHQ significantly increased their activities. n = 5 in A and n = 4 in B for each data point. * Indicates p < 0.05, compared to control group dative stress was found in the cells treated with tBHQ (r = ±0.99, p < 0.05).
The troglitazone-induced increase in oxidative stress was time-dependent in H11 cells. A significant increase in oxidative stress was observed after the cells were treated with troglitazone (100 mmoles/l) as early as 30 min after the exposure to troglitazone. Within 2 h, this increase in oxidative stress gradually subsided. However, the troglitazone treatment beyond 2 h produced the second tide of oxidative stress which increased linearly up to 24 h (Fig. 7A) . A similar pattern of time-dependent changes was also found in the activity of glyoxalase I in the presence of troglitazone. The inhibitory effect of troglitazone on the activity of glyoxalase I was not significant until the incubation time was 4 h or longer (Fig. 7A) . On the other hand, there was no significant change in the cellular GSH level after the treatment of cells with troglitazone (100 mmoles/l) at time intervals from 30 min to 24 h (data not shown). To investigate whether the troglitazone-inhibited activity of glyoxalase I was secondary to the increase in the cellular oxidative stress, the time-dependent effects of tBHQ or xanthine-xanthine oxidase on the activity of glyoxalase I as well as on the cellular oxidative stress levels were examined. There were no significant changes in the activity of glyoxalase I after the cells were treated with tBHQ (100 mmoles/l) at different time intervals (Fig 7B) . A time-dependent biphasic change in oxidative stress was observed after the cells were treated with tBHQ (Fig. 7B) . Within 1 h of treatment, the oxidative stress was increased. A prolonged incubation beyond 6 h, however, resulted in a reduction in oxidative stress. The time-dependent activation of phase 2 enzymes, leading to the generation of GSH, might be responsible for this biphasic effect of tBHQ. In an- The oxidative stress and glyoxalase I activity were determined after the treatment of cells with: A troglitazone (100 mmol/l), B tBHQ (100 mmol/l) or C xanthine (X: 150 mmol/l)-xanthine oxidase (XO: 15 mU/ml) at different times. n = 4 per data point. * Indicates p < 0.05, compared to control group other group of experiments, xanthine (150 mmol/l)-xanthine oxidase (15 mU/ml) generated a significant oxidative stress during the 24 h treatment but had no effect on the activity of glyoxalase I (Fig 7C) .
In contrast to what was found in the H11 cells, troglitazone did not increase oxidative stress in rat hepatocytes.
The effect of troglitazone and rosiglitazone on glyoxalase I mRNA levels. To examine whether reduced glyoxalase I enzyme activity was correlated with decreased mRNA contents, troglitazone was added to cultures of H11 cells and RNA isolated after 8 h. Glyoxalase I mRNA contents were reduced relative to RPPO mRNA with 100 mmol/l troglitazone causing a 40 % decrease in mRNA (Fig. 8 ) in H11 cells. When this was repeated in another set of experiments with troglitazone exposure time increased to 24 h, glyoxalase I mRNA decreased by 65 % (data not shown). These reductions in mRNA correlate well with those in glyoxalase I enzyme activity. To determine whether this troglitazone-induced reduction in glyoxalase I mRNA is also present in other cell types, the effect of an 8 h exposure to troglitazone on glyoxalase I mRNA was examined in rat cardiac myocytes and hepatocytes. In these cell types, troglitazone caused a marked (85 % and 65 % respectively) reduction in glyoxalase I mRNA (Fig. 8) .
To determine whether a decrease in glyoxalase I expression was a general property of all members of the thiazolidinedione family, the effect of rosiglitazone on glyoxalase I expression was examined in primary hepatocytes. Rosiglitazone had no effect on glyoxalase I expression (Fig. 9 ).
Discussion
Our data show that troglitazone down-regulates glyoxalase I mRNA content in at least three cell types: human astroglioma cells, rat cardiac myocytes and rat hepatocytes. The reduced glyoxalase I mRNA content correlated with a reduction in glyoxalase I enzyme activities in the cells examined, the human astroglioma cells and rat hepatocytes. In addition, lower glyoxalase I expression was associated with lower glyoxalase II activity. The inhibitory effect of troglitazone on the activity of glyoxalase I was concentration-dependent and time-dependent. This down-regulation does not seem to be a non-specific effect because troglitazone had no effect on the GSH contents, glutathione Stransferase activity or thioredoxin reductase activity. Furthermore, tBHQ increased GSH, glutathione Stransferase and thioredoxin reductase but had no effect on glyoxalase I and II activities.
Methylglyoxal and other a-oxo-aldehydes give rise to AGEs [3] . Prolonged inhibition of the glyoxalase system might be expected to result in problems of increased advanced AGE production. Our study found A B C Fig. 8 . Effect of an 8 h exposure to troglitazone on glyoxalase I (Gly 1) mRNA in human H11 astroglioma cells (A), rat cardiac myocytes (B) and rat primary hepatocytes (C). In the same Northern blots the RPP0 mRNA content was also determined and Gly I mRNA relative to RPP0 mRNA is plotted in arbitrary density units at the bottom of each figure   Fig. 9 . Effect of an 8 h exposure to rosiglitazone on glyoxalase I (Gly 1) mRNA in rat primary hepatocytes. In the same Northern blots the RPP0 mRNA content was also determined that the decrease in glyoxalase I and II activities did correlate with increased AGE formation. Such AGEs can interact with either receptors for advanced glycation endproducts or with scavenger receptors [37] . Activation of such receptors can activate the respiratory burst, thereby increasing oxidative stress.
An inhibition of the glyoxalase system could help explain troglitazone-induced hepatotoxicity [38±40], particularly our observation that troglitazone increased oxidative stress in H11 human astroglioma cells, but not in rat hepatocytes. Our studies show troglitazone or a metabolite is a pro-oxidative agent in human astroglioma cells. One reason why troglitazone could be a pro-oxidant intracellularly is that in human beings, troglitazone is oxidized to a quinonelike compound by a number of cytochrome P450 s (CYPs) including CYP1A1, CYP2C8, CYP2C19 and CYP3A4 [41] . Quinones can undergo redox cycling resulting in the formation of superoxide anion [42] , thereby increasing oxidative stress. Troglitazone is not only metabolized by CYP3A4 but it also induces CYP3A4 in both human and rat hepatocytes [43] . Quinone redox cycling could account for the prolonged rise in oxidative stress in the human cells that we saw in our experiments. That no oxidative stress was observed in rat hepatocytes following exposure to troglitazone could be due to differences in metabolism of troglitazone between rat and human cells.
As indicated by previous experiments [44] , the suppression of glyoxalase system where there is also an increase in the oxidative stress experienced by the cell could be deleterious for the cell, tissue and organ. The suppression of the glyoxalase system together with the reduced efficiency with which troglitazone is metabolized into a quinone, induces CYP3A4 or down-regulates the glyoxalase system or both and could be what determines which patients develop troglitazone-induced hepatotoxicity, a hepatoxicity with similarities to acetaminophen toxicity. Because there is allelic variation in both the CYP3A4 gene [45] and in the glyoxalase I gene [46, 47] there could well be differences amongst individuals in how readily troglitazone induces oxidative stress and how readily troglitazone down-regulates the glyoxalase system, thus possibly explaining why approximately 2 % of patients receiving troglitazone [40] develop liver problems.
It is not known whether the troglitazone-induced reduction in glyoxalase I is due to reduced mRNA stability or to reduced mRNA synthesis, although the latter is the more common mode of regulation. Troglitazone is a ligand for PPARg [48] and many of the antihyperglycaemic and insulin-sparing effects of troglitazone appear due to the activation of this nuclear receptor [15] . One example of gene expression suppression by troglitazone is the inhibition of phosphoenolpyruvate carboxykinase gene expression [13] . Here, inhibition of phosphoenolpyruvate carboxykinase by troglitazone is likely to occur through the activation of PPARg because there are several PPAR consensus sequences in the promoter region of the gene [49] . Even if troglitazone reduces the transcription of glyoxalase I, it is not clear how it does so because there is no PPAR consensus sequence in the promoter region of glyoxalase I [50] . The thiazolidinedione BRL49 653 also activates the PPARg receptor to down-regulate ob gene expression; however, there are no PPAR consensus sequences in the ob promoter region [51] . Rather activated PPARg down-regulates ob gene expression by inhibiting C/EBP-induced activation of the promoter [52] . Interestingly, there is also a C/EBP consensus site in the promoter region of glyoxalase I [50] , and it could well be that a similar mechanism is at work in troglitazone's suppression of glyoxalase I gene expression. Also of interest is that there is a C/EBP consensus site in the promoter region of the PPARg gene [53] , a gene whose promoter has no PPAR consensus sites but that is up-regulated by troglitazone [54] .
In conclusion, troglitazone caused a specific decrease in glyoxalase I and II activities and a reduction in glyoxalase I mRNA activities. Rosiglitazone, on the other hand, had no effect on glyoxalase I gene expression. Rosiglitazone is a thiozolidinedione with no known hepatotoxic activity [55] . The inhibition of the glyoxalase system and the concurrently increased oxidative stress could possibly account for the hepatotoxicity occasionally observed following prolonged treatment with troglitazone.
